Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial

2016 ASCO Annual Meeting
Tweet this page

Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion (Abstract LBA2000).

Advertisement

Advertisement



Advertisement

click me